The Proprietary Mebias Discovery Platform 19Fluid


Detect fluid/solution dynamic conformation of full length GPCRs

    • Proprietary purification of native, full-length GPCR
    • Protein NMR with proprietary 19F labeling scheme to capture coupling of scaffold proteins (G-protein, beta-arrestin) to GPCR

Empowers drug discovery beyond current state of the art

Platform is agnostic to therapeutic area

Successfully applied to multiple targets

    • MOR, DOR
    • S1PR1
    • β1AR, β2AR
    • Additional GPCRs have been expressed and purified as potential targets  (e.g., MLNR, A2A)

Uncovering extremely signaling-pathway selective mu-opioid receptor agonists